Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics



    - Data to be presented at International Shock Congress by sepsis thought
    leaders -

    TORONTO, June 26 /CNW/ - Spectral Diagnostics Inc. (TSX: SDI) today
announced the presentation of data that demonstrates the combined clinical
effectiveness of its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared
diagnostic for the measurement of endotoxin, to identify patients with
elevated endotoxin levels and to guide endotoxin reducing strategies, such as
Toray Medical's therapeutic column, Toraymyxin(TM). The presentations will be
made at a symposium entitled "Blood Purification in the Treatment of Sepsis,"
at the International Shock Congress in Cologne, Germany to be held from June
28-July 2.
    "Several of the presentations at this important congress use data
collected with Spectral's EAA(TM) and highlight the value of our product, both
independently and in combination with anti-endotoxin therapies," said
Dr. Paul Walker, President and CEO of Spectral. "Increasingly, EAA(TM) and
Toray's therapeutic column, Toraymyxin(TM), which removes endotoxin from the
bloodstream, are being recognized as a valuable combination for the diagnosis,
treatment and monitoring of patients with severe sepsis."
    The "Blood Purification in the Treatment of Sepsis" symposium will be
held on July 1, from 8:30-10:00AM CEST. Speakers presenting data using EAA(TM)
include Dr. David Klein of St. Michael's Hospital in Toronto, Canada, who will
deliver a presentation entitled, "The Endotoxin Activity Assay (EAA(TM)) as a
diagnostic tool for anti-endotoxin sepsis treatment". Dr. Eugen Faist of the
University of Munich in Germany will speak about, "Endotoxemia and immune
profiles of patients with acute sepsis due to major peritonitis". Information
on the meeting, including the full scientific program, can be seen at
www.shocksociety.org.

    About Spectral Diagnostics

    Spectral is a leader in the battle against sepsis. Spectral's lead
product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay
for the measurement of endotoxin. With the growing awareness for the role of
endotoxemia in sepsis and the increasing number of therapies being developed
for this indication, Spectral is well-positioned to drive the adoption of the
EAA(TM), which can be used to identify patients, enable therapeutics and
monitor treatment. Spectral is listed on TSX under the symbol SDI.

    Forward-looking statement

    Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.

    %SEDAR: 00002006E




For further information:

For further information: Dr. Paul Walker, President & CEO, (416)
626-3233 ex. 2100; James Smith, Investor Relations, (416) 815-0700 ext. 229,
jsmith@equicomgroup.com

Organization Profile

Spectral Diagnostics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890